1. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial 
Prof Ousmane A Koita, PhD, Lansana Sangaré, PhD, Haiyan D Miller, BS, Aliou Sissako, MD, Moctar Coulibaly, MD, Trevor A Thompson, BS, Prof Saharé Fongoro, MD, Youssouf Diarra, PharmD, Mamadou Ba, PhD, Prof Ababacar Maiga, PhD, Prof Boubakar Diallo, MD, David M Mushatt, MD, Frances J Mather, PhD, Jeffrey G Shaffer, PhD, Asif H Anwar, MD, Prof Donald J Krogstad, MD 
The Lancet Infectious Diseases 
Volume 17, Issue 12, Pages (December 2017)
DOI: /S (17)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

2. Figure 1
Trial profile
*Individuals with fever, chills, or other symptoms consistent with malaria were screened with blood smears, physical examinations (including temperatures), and previous medical records. †These participants were excluded because they had negative blood smears for asexual Plasmodium falciparum parasites or less than 2000 asexual parasites per μL.
The Lancet Infectious Diseases  , DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

3. Figure 2 Kaplan-Meier plot for parasite clearance times
Proportion of participants with positive blood smears after treatment with artemether and lumefantrine versus AQ-13.
The Lancet Infectious Diseases  , DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

4. Figure 3
Mean blood concentrations of AQ-13 after oral treatment from days 1 to 8
Mean blood concentrations of AQ-13 after treatment with 1596·25 mg of AQ-13 base on days 1–3 are based on serial 5·0 mL venous blood samples from 17 participants randomly assigned to and given AQ-13 in Error bars are 95% CIs. The mean AQ-13 blood concentrations observed 7–8 days after the start of treatment (800–1000 nM) were 40–50-times greater than the IC50s for chloroquine-resistant Plasmodium falciparum in vitro (15–20 nM).7,8 IC50s=50% inhibitory concentrations.
The Lancet Infectious Diseases  , DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions